Quibim
Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma
Quibim is the go-to for enterprise radiology and biopharma needing regulatory-cleared quantitative biomarkers, especially prostate and breast MRI. Its multi-omics integration and global reach are unmatched, but the enterprise-only pricing and specialty focus exclude small clinics and emergency use.
Verified 4d ago · liveness 71/100 · cite: rightaichoice.com/tools/quibim
- Radiologists needing quantitative biomarkers for prostate, brain, liver, breast, or lung MRI
- Biopharma companies seeking AI-driven patient stratification and drug response monitoring
- Clinical researchers analyzing multi-omics and large-scale imaging datasets
- Hospitals requiring HIPAA/GDPR-compliant cloud imaging with regulatory clearances
- Small clinics with limited budget and no enterprise IT support
- Emergency radiology (stroke, fracture detection) – not a primary use case
- Users wanting a free or low-cost AI tool – pricing is enterprise-only
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Quibim if you are a small clinic with a limited budget needing a low-cost, all-in-one AI tool or emergency radiology capabilities like stroke detection—this platform is enterprise-focused and priced accordingly.
Enterprise-only pricing with no public tiers—you must contact sales, and costs scale with the number of sites and imaging volume.
Quibim's pricing is enterprise-only, typically suitable for large hospitals and biopharma companies with substantial budgets. Compared to general-purpose imaging AI tools that offer per-study or subscription pricing, Quibim's cost is likely higher but justified by regulatory clearances and quantitative biomarkers. For smaller practices, cheaper alternatives like Lunit or Gleamer may suffice.
In short
Quibim — Regulatory-cleared quantitative imaging biomarkers from MRI, CT, and PET for radiology and biopharma. Best for Radiologists needing quantitative biomarkers for prostate, brain, liver, breast, or lung MRI, Biopharma companies seeking AI-driven patient stratification and drug response monitoring, Clinical researchers analyzing multi-omics and large-scale imaging datasets. Contact Sales pricing.
What's new in Quibim
Checked 4 days agoAcross the latest 1 update: 1 feature update.
What people actually say about Quibim — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
9 mentions across 1 source (YouTube) · researched Aug 21, 2026.
- +Regulatory clearances (FDA, CE, Health Canada) give clinical credibility.
- +Tissue-agnostic platform for diverse imaging biomarker extraction.
- +Integrates with PACS for smooth clinical workflow.
- +HIPAA, GDPR, ISO 27001 compliance ensures data security.
- +Linking imaging with EHR and multi-omics supports biomarker discovery.
- −Nearly zero independent community feedback online.
- −Lack of public user success stories or case studies.
- −Pricing opaque, likely enterprise-level costs.
- −No evidence of simple self-service deployment; requires enterprise IT.
- −Advanced skill level may deter smaller practices.
- • No public pricing; may require annual contracts and Azure usage fees.
- • Possibly per-scan or per-module fees for each QP product.
Viability Score
How well maintained and how widely used is Quibim? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: August 2026
How we score →Key Features
- Tissue-agnostic radiomics feature extraction
- QP-Prostate: PI-RADS-compliant prostate MRI analysis (FDA, CE, Health Canada licensed)
- QP-Brain: brain volumetry and white matter hyperintensity (WMH) analysis
- QP-Liver: liver fat and iron concentration quantification
- QP-Breast: CE and UKCA-marked AI for breast cancer detection via MRI (launched July 2026)
- QP-Lung: lung imaging analysis
- QP-Insights: imaging data management, harmonization, and multi-omics linking
- Integration with PACS for clinical workflow
- Automated segmentation and quantification for prostate, brain, liver, breast, and lung
- Link imaging with EHR and multi-omics data for biomarker discovery
- Cloud-based on Microsoft Azure with secure storage
- ISO 27001:2022, HIPAA, and GDPR compliance
- RBAC verification time reduced by 90% (June 2026)
- Patient stratification for clinical trials and drug response monitoring
About Quibim
Quibim is a cloud-based, tissue-agnostic platform that transforms medical images into quantitative biomarkers for radiologists, biopharma companies, and clinical researchers. It extracts radiomics and deep learning features from imaging data, linking them with EHR and multi-omics information to support biomarker discovery and patient stratification. The platform runs on Microsoft Azure with ISO 27001:2022 certification and HIPAA/GDPR compliance, ensuring secure data handling. Quibim offers a suite of regulatory-cleared specialty products. QP-Prostate® provides PI-RADS-compliant prostate MRI analysis (FDA, CE, Health Canada licensed). QP-Brain® performs brain volumetry and white matter hyperintensity (WMH) analysis. QP-Liver® quantifies liver fat and iron concentration, while QP-Lung® supports lung imaging analysis. QP-Breast® is the first CE and UKCA-marked AI tool for breast cancer detection via MRI in Europe and the UK, launched July 2026. QP-Insights® orchestrates imaging data management, harmonization, and linking with EHRs and multi-omics. These tools integrate with PACS for clinical workflow, and QP-Insights provides a one-stop-shop for handling large-scale imaging data. The platform has over 50 active sites and a registry of over 200K de-identified cancer patients, supporting real-world evidence for drug development and clinical trials. A recent update reduced RBAC verification time by 90%, improving deployment efficiency. Compared to general-purpose imaging AI, Quibim focuses on quantitative, tissue-specific biomarkers with regulatory clearances across regions, making it a strong fit for enterprise healthcare and life sciences teams that need validated, standardized measurements.
Behind the Verdict
Quibim stands out in the medical imaging AI space by focusing on quantitative biomarkers rather than simple lesion detection. Its products are regulatory-cleared (FDA, CE, Health Canada, UKCA), which is a significant advantage for clinical adoption and reimbursement. The platform's integration with PACS and its ability to harmonize imaging data across manufacturers reduce variability, making it particularly valuable for multi-site clinical trials. Strengths: Deep specialization in prostate, brain, liver, breast, and lung imaging; strong regulatory portfolio; robust data security (ISO 27001, HIPAA, GDPR); and the ability to link imaging with EHR and multi-omics data, enabling biomarker discovery and patient stratification. Weaknesses: Enterprise-only pricing (no public tiers) limits accessibility for small practices; the need for specific product purchases can complicate budgeting; and integration with existing hospital IT may require significant effort. For emergency radiology (stroke, fractures) or general-purpose AI, other tools may be more suitable. Where it fits: Large hospitals, health systems, and biopharma companies running clinical trials or needing reproducible imaging biomarkers. Where it doesn't: small clinics with limited IT support or those seeking a low-cost, all-in-one AI package.
Researching Quibim? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Quibim actually fits — and what changes day-one when you adopt it.
You use QP-Prostate integrated with your PACS to read prostate MRIs. The AI provides PI-RADS-compliant scoring and volumetric measurements, reducing interpretation time and increasing consistency across your department.
Outcome: You deliver standardized prostate MRI reports, improving diagnostic confidence and reducing variability among radiologists.
You use QP-Insights to harmonize imaging data from multiple sites, link it with EHR and multi-omics data, and run AI models to identify patients likely to respond to a new drug.
Outcome: You accelerate patient recruitment and can monitor treatment response and toxicity more accurately, supporting regulatory submissions.
You apply QP-Brain to longitudinal MRI scans of patients with neurodegenerative diseases, automatically computing brain volumetry and WMH metrics.
Outcome: You obtain objective, reproducible measures to track disease progression and evaluate therapeutic efficacy in your studies.
Use Cases
- Identify clinical trial candidates based on imaging biomarkers from routine scans
- Quantify tumor heterogeneity and predict treatment response in lung cancer
- Standardize prostate MRI reads with PI-RADS-compliant AI analysis
- Monitor liver steatosis and iron overload non-invasively over time
- Accelerate brain volumetry for neurodegenerative disease diagnosis and progression tracking
- Stratify neuroblastoma patients using AI algorithms from PET/CT images
- Predict survival and neurotoxicity in B-Cell lymphoma patients treated with CAR-T therapy
Models Under the Hood
as of 2026-08-30
Limitations
- Quibim provides regulatory-cleared AI-based imaging biomarkers for MRI, CT, and PET, with products such as QP-Prostate, QP-Brain, QP-Liver, QP-Breast, QP-Lung, and QP-Insights.
- The platform is cloud-based, integrates with PACS, and is designed for radiology and biopharma use, but specific pricing is not disclosed and some product details are limited.
- Integration with existing hospital systems may require significant effort.
as of 2026-08-29
Verification history
We have re-verified Quibim 16 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 16 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Quibim's pricing actually pencils out — and where peers do it cheaper.
Quibim's pricing is enterprise-only, typically suitable for large hospitals and biopharma companies with substantial budgets. Compared to general-purpose imaging AI tools that offer per-study or subscription pricing, Quibim's cost is likely higher but justified by regulatory clearances and quantitative biomarkers. For smaller practices, cheaper alternatives like Lunit or Gleamer may suffice.
Setup time & first value
How long it actually takes to get something useful out of Quibim — broken out by persona, not the marketing-page minute.
For a radiologist using QP-Prostate integrated with PACS, initial setup can be completed within days, since it is designed to work within existing workflows. For enterprise deployments involving QP-Insights and multi-site data harmonization, expect several weeks to configure integrations, validate, and train staff.
Switching to or from Quibim
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From manual or semi-automated prostate MRI reading: QP-Prostate integrates with your PACS, allowing radiologists to adopt AI-assistance with minimal disruption to existing reporting workflows.
- ↗To a general-purpose imaging AI platform: You would need to export your quantitative imaging data and consult the new vendor's data migration services, as Quibim's outputs are specialized biomarker measures.
Integrations
Resources & Guides
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
- Resourcequibim.com
Info Hub - AI Imaging, Radiomics & Clinical Insights
Blog, white papers, scientific publications, webinars and KOL conversations on AI applied to medical imaging. Curated by Quibim — pioneers in radiomics.
Tutorials & Learning
Official links
Tools that pair well with Quibim
Common stack mates teams adopt alongside Quibim, with the specific reason each pairing earns its keep.
Alternatives to Quibim
View allRecursion Pharmaceuticals
AI-native drug discovery platform turning 50+ PB of cellular imaging data into clinical-stage therapies
Frequently Asked Questions
Used Quibim? Help shape our editorial sentiment research.